Search
Close this search box.

Accuracy
when lives are on the line

LifeScale combines time-tested AST methods with the most advanced measurement technology to provide fast and accurate phenotypic AST results.

Home / Products

Long-Incubation Results
in a Fraction of the Time

The same well plates and antibiotics used in gold-standard ASTs are inoculated using positive blood culture without the delay of solid media culturing. After incubating only 3 hours, the well plates are measured using a unique microfluidic sensor that measures individual microbes from each well. This rich data set is then processed using advance AI to produce results as accurate as conventional phenotypic ASTs, but in only 4 ½ hours.   

LifeScale’s Patented Technology Featuring Population Profiling and AI-Predictor™

The key to LifeScale’s fast and accurate results is population profiling. A tiny aliquot from each well is passed through its microfluidic sensor, which detects and counts several microbes. This data allows LifeScale to measure precisely whether microbes in each well have replicated even in LifeScale’s short incubation time. Unlike other ASTs, the sensor also measures their individual masses to detect their response to antibiotics even in cases where replication may be delayed several hours. With the help of LifeScales’ AI-Predictor™, accurate MICs are produced even for the most challenging resistant strains. This population-level information is not available to ASTs that measure bulk culture growth or metabolism, or that assess single microbes or colonies. As a result, LifeScale provides both the shortest turnaround time and most accurate results among rapid ASTs.   

“When evaluating the performance and reliability of a technology, additional factors that are integral to assuring the success of the technology are impact on workflow and labor (“hands on time”). If the latter two are disruptive to current workflow requiring reorganization, and require additional expenditure of labor, it is highly unlikely that the new technology will be accepted or successful. LifeScale Rapid AST supports improved workflow and minimizes labor.”

– Dr. James Snyder (Ph.D., D(ABMM), F(AAM))

“When evaluating the performance and reliability of a technology, additional factors that are integral to assuring the success of the technology are impact on workflow and labor (“hands on time”). If the latter two are disruptive to current workflow requiring reorganization, and require additional expenditure of labor, it is highly unlikely that the new technology will be accepted or successful. LifeScale Rapid AST supports improved workflow and minimizes labor.”

– Dr. James Snyder (Ph.D., D(ABMM), F(AAM))

Department of Pathology and Laboratory Medicine
University of Louisville Hospital

LifeScale in Your Lab

Seamless Integration into Optimized Workflows

LifeScale is designed to fit easily into your workflow, while also being easy to use and cost effective. LifeScale tests your Gram-negative blood culture samples – the ones for which rapid results are most important – while other samples continue to be tested with your trusted AST standard of care. This focused approach is cost-effective, with little impact to your carefully optimized workflow. LifeScale can be used with your lab’s established BCID system, and can process up to 4 ASTs in parallel, supporting the rapid AST sample volumes of most hospitals. LifeScale’s AST kits are compact and can be stored at room temperature for up to a year.

Proven

in the Field

LifeScale’s performance, reliability, and ease of use have been proven in the field. Results at a 600-bed hospital matched the accuracy of a respected standard of care and were available in only 4 ½ hours. 

Test Roadmap
Expanding Our Diagnostic Footprint

We won’t stop with Gram-negative bacteria in positive blood culture. LifeScale’s platform is extensible to the range of phenotypic ASTs for which rapid results can help your patients. Antifungal testing from blood culture, high-value isolates, and other direct-from-sample tests such as acute UTIs and BALs are on the LifeScale roadmap. Contact us to find out more. 

Test Roadmap
Expanding Our Diagnostic Footprint

We won’t stop with Gram-negative bacteria in positive blood culture. LifeScale’s platform is extensible to the range of phenotypic ASTs for which rapid results can help your patients. Antifungal testing from blood culture, high-value isolates, and other direct-from-sample tests such as acute UTIs and BALs are on the LifeScale roadmap. Contact us to find out more. 

Put LifeScale to the test in your lab, today.